FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385969475> ?p ?o ?g. }

• W4385969475 endingPage "2752" @default.
• W4385969475 startingPage "2741" @default.
• W4385969475 abstract "Abstract The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI) toxicity typically occurs early after treatment initiation, physicians often tend to start therapy with lower doses although this has never been tested systematically in prospective trials in the Western world. The Bo sutinib Do se Optimization (BODO) Study, a multicenter phase II study, investigated the tolerability and efficacy of a step-in dosing concept of bosutinib (starting at 300 mg QD) in chronic phase CML patients in 2 nd or 3 rd line who were intolerant and/or refractory to previous TKI treatment. Of 57 patients included until premature closure of the study due to slow recruitment, 34 (60%) reached the targeted dose level of 500 mg QD following the 2-weekly step-in dosing regimen. While the dosing-in concept failed to reduce GI toxicity (grade II–IV, primary study endpoint) to < 40% (overall rate of 60%; 95% CI: 45–74%), bosutinib treatment (mean dosage: 403 mg/day) showed remarkable efficacy with a cumulative major molecular remission (MMR) rate of 79% (95% CI: 66 to 88%) at month 24. Of thirty patients refractory to previous therapy and not in MMR at baseline, 19 (64%) achieved an MMR during treatment. GI toxicity did not significantly impact on patient-reported outcomes (PRO) and led to treatment discontinuation in only one patient. Overall, the results of our trial support the efficacy and safety of bosutinib after failure of second-generation TKI pre-treatment. Trial registration: NCT02577926." @default.
• W4385969475 created "2023-08-19" @default.
• W4385969475 creator A5002753518 @default.
• W4385969475 creator A5005641797 @default.
• W4385969475 creator A5007614326 @default.
• W4385969475 creator A5009383961 @default.
• W4385969475 creator A5010461455 @default.
• W4385969475 creator A5013024565 @default.
• W4385969475 creator A5013968213 @default.
• W4385969475 creator A5023015071 @default.
• W4385969475 creator A5028134574 @default.
• W4385969475 creator A5032138074 @default.
• W4385969475 creator A5034952245 @default.
• W4385969475 creator A5035964802 @default.
• W4385969475 creator A5038048953 @default.
• W4385969475 creator A5043227502 @default.
• W4385969475 creator A5048469868 @default.
• W4385969475 creator A5049367139 @default.
• W4385969475 creator A5053069175 @default.
• W4385969475 creator A5057631300 @default.
• W4385969475 creator A5059485343 @default.
• W4385969475 creator A5061229750 @default.
• W4385969475 creator A5061879279 @default.
• W4385969475 creator A5062159577 @default.
• W4385969475 creator A5062333664 @default.
• W4385969475 creator A5066994665 @default.
• W4385969475 creator A5073313603 @default.
• W4385969475 creator A5090648381 @default.
• W4385969475 date "2023-08-18" @default.
• W4385969475 modified "2023-10-18" @default.
• W4385969475 title "Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study" @default.
• W4385969475 cites W1562740173 @default.
• W4385969475 cites W1919069136 @default.
• W4385969475 cites W1973617793 @default.
• W4385969475 cites W2057796192 @default.
• W4385969475 cites W2059705970 @default.
• W4385969475 cites W2112918550 @default.
• W4385969475 cites W2115626434 @default.
• W4385969475 cites W2137591261 @default.
• W4385969475 cites W2141106022 @default.
• W4385969475 cites W2156145496 @default.
• W4385969475 cites W2766187515 @default.
• W4385969475 cites W2790536087 @default.
• W4385969475 cites W2801409342 @default.
• W4385969475 cites W2804990894 @default.
• W4385969475 cites W2910542347 @default.
• W4385969475 cites W3009751715 @default.
• W4385969475 cites W3036304464 @default.
• W4385969475 cites W3095325704 @default.
• W4385969475 cites W3132035324 @default.
• W4385969475 cites W3156088103 @default.
• W4385969475 cites W3169809195 @default.
• W4385969475 cites W3172717443 @default.
• W4385969475 cites W3195599002 @default.
• W4385969475 cites W4214806085 @default.
• W4385969475 cites W4281951662 @default.
• W4385969475 doi "https://doi.org/10.1007/s00277-023-05394-0" @default.
• W4385969475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37592092" @default.
• W4385969475 hasPublicationYear "2023" @default.
• W4385969475 type Work @default.
• W4385969475 citedByCount "1" @default.
• W4385969475 crossrefType "journal-article" @default.
• W4385969475 hasAuthorship W4385969475A5002753518 @default.
• W4385969475 hasAuthorship W4385969475A5005641797 @default.
• W4385969475 hasAuthorship W4385969475A5007614326 @default.
• W4385969475 hasAuthorship W4385969475A5009383961 @default.
• W4385969475 hasAuthorship W4385969475A5010461455 @default.
• W4385969475 hasAuthorship W4385969475A5013024565 @default.
• W4385969475 hasAuthorship W4385969475A5013968213 @default.
• W4385969475 hasAuthorship W4385969475A5023015071 @default.
• W4385969475 hasAuthorship W4385969475A5028134574 @default.
• W4385969475 hasAuthorship W4385969475A5032138074 @default.
• W4385969475 hasAuthorship W4385969475A5034952245 @default.
• W4385969475 hasAuthorship W4385969475A5035964802 @default.
• W4385969475 hasAuthorship W4385969475A5038048953 @default.
• W4385969475 hasAuthorship W4385969475A5043227502 @default.
• W4385969475 hasAuthorship W4385969475A5048469868 @default.
• W4385969475 hasAuthorship W4385969475A5049367139 @default.
• W4385969475 hasAuthorship W4385969475A5053069175 @default.
• W4385969475 hasAuthorship W4385969475A5057631300 @default.
• W4385969475 hasAuthorship W4385969475A5059485343 @default.
• W4385969475 hasAuthorship W4385969475A5061229750 @default.
• W4385969475 hasAuthorship W4385969475A5061879279 @default.
• W4385969475 hasAuthorship W4385969475A5062159577 @default.
• W4385969475 hasAuthorship W4385969475A5062333664 @default.
• W4385969475 hasAuthorship W4385969475A5066994665 @default.
• W4385969475 hasAuthorship W4385969475A5073313603 @default.
• W4385969475 hasAuthorship W4385969475A5090648381 @default.
• W4385969475 hasBestOaLocation W43859694751 @default.
• W4385969475 hasConcept C121608353 @default.
• W4385969475 hasConcept C126322002 @default.
• W4385969475 hasConcept C143998085 @default.
• W4385969475 hasConcept C197934379 @default.
• W4385969475 hasConcept C203092338 @default.
• W4385969475 hasConcept C2777288759 @default.
• W4385969475 hasConcept C2777583451 @default.
• W4385969475 hasConcept C2778208673 @default.
• W4385969475 hasConcept C2778375690 @default.

• next